PeriPure 2.5% Solution

Adult administration

Generally, for adults, 1.5 to 2.5L is injected into the abdominal cavity per session. For continuous ambulatory peritoneal dialysis, the draining process is performed 3 to 5 times a day after a 4 to 8-hour dwell time. For automated peritoneal dialysis, cycles of 4 to 5 are performed overnight, and up to 2 cycles during the day.

This medication is for peritoneal dialysis and ceasing dialysis treatment can result in the complete failure of kidney function, which can be life-threatening. Certain patient groups should not use this medication. For example, patients with diaphragm defects, abdominal burns, or severe peritoneal adhesions may experience respiratory distress, treatment interference, or reduced dialysis efficiency if this medication is administered. Patients with a bleeding risk, suspected lactic acid metabolism disorders, severe electrolyte imbalances, recent abdominal surgery or trauma, inflammatory bowel disease, abdominal fistula or tumors, abdominal hernias, bowel obstruction, severe pulmonary disease, sepsis, and others are prohibited from administration of this drug. Additionally, patients with cachexia or severe weight loss, and those who cannot carry out peritoneal dialysis under the guidance of a physician should be administered cautiously. When using this drug, patients taking digitalis preparations, suspected of having glucose metabolism disorders, with lumbar disorders, colostomy patients, those taking diuretics, patients with severe ventilation disorders, severely obese patients, immunocompromised patients, pregnant women, those with peritonitis, or hyperparathyroidism need to be monitored closely, and regular blood tests and status monitoring are essential. Local adverse reactions such as abdominal pain, bleeding, peritonitis, catheter-related inflammation, catheter breakage, difficulty draining, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal distension, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoalbuminemia, hyperglycemia, breathing difficulties due to diaphragm elevation, and respiratory issues related to electrolyte disorders may occur. Peritoneal dialysis solutions must be handled aseptically and cleanly, and before use, the integrity and clarity of the container must be confirmed. During dialysis, fluid balance must be managed appropriately, and weight and blood tests should be regularly checked to prevent excessive fluid accumulation or electrolyte imbalances. Safety for pregnant or nursing women is not well established, therefore this medication should only be used cautiously when therapeutic benefits outweigh risks. In pediatrics, solution dosing should be adjusted according to weight and age, and geriatric patients should be considered for the risk of herniation. Overdosage may cause dehydration, electrolyte disturbances, and hyperglycemia. Immediate medical attention is necessary. Finally, this drug is to be used only for peritoneal dialysis and should not be administered as an injection; it needs to be stored away from direct sunlight and frozen conditions, at room temperature.

Serious side effects

Peritonitis (may include abdominal pain, cloudy effluent, fever), bowel obstruction, respiratory distress due to diaphragm defects, sepsis, signs of peritonitis (including abdominal pain, cloudy drainage, fever), severe edema, significant weight loss, edema accompanied by increased blood pressure, possibility of severe allergic reactions.

Mild side effects

Abdominal pain, bleeding, peritonitis, inflammation around the abdominal catheter, catheter breakage, difficulty draining, nausea, diarrhea, constipation, hemorrhoids, vomiting, loss of appetite, abdominal bloating, hypokalemia, hyponatremia, hypocalcemia, hypophosphatemia, hyperlactatemia, hypomagnesemia, hypercholesterolemia, hypertriglyceridemia, metabolic acidosis, hypoalbuminemia, hyperglycemia, breathing difficulties due to diaphragm elevation, respiratory issues related to electrolyte disturbances.

This drug should be stored in a sealed container to prevent air ingress, and should not be frozen but kept in a cool place at temperatures below 25 degrees Celsius. Proper storage will help maintain the drug's efficacy for a longer duration.

Appearance

This drug is a transparent peritoneal dialysis solution in a pale yellow color contained in a colorless, transparent plastic bag with two chambers.

Package unit

2L/bag (A solution:B solution = 725:1275), 3L/bag (A solution:B solution = 1087.5:1912.5)